Sign in

Ilya Zubkov

Senior Equity Research Analyst at Freedom Broker

Ilya Zubkov is a Senior Equity Research Analyst at Freedom Broker, specializing in equity research across multiple sectors. He has provided coverage on high-profile companies such as Sarepta Therapeutics, where his recent 'Buy' recommendation reflected a significant upside, with a published target price implying a potential return exceeding 100%. Zubkov's career in equity analysis is based at Freedom Broker, where he leverages his expertise in evaluating market opportunities and providing actionable investment research, though earlier roles and licensing details are not publicly documented. While he does not disclose FINRA registration or specific securities licenses, his coverage is featured on major performance tracking platforms like TipRanks, where his actionable calls and metrics are publicly monitored.

Ilya Zubkov's questions to VIEMED HEALTHCARE (VMD) leadership

Question · Q2 2025

Ilya Zubkov from Freedom Broker asked about the drivers behind the significant increase in sleep therapy patients and the reasons for the sequential revenue decline in the staffing business.

Answer

COO & Director Todd Zehnder attributed the sleep therapy growth to an expanded sales effort and operational improvements, noting GLP-1s may be a positive tailwind. CFO Trae Fitzgerald added that a lag between new patient setups and their entry into the resupply program points to future growth. Regarding staffing, CEO & Director Casey Hoyt explained the sequential slowdown was due to the timing of state government contracts for behavioral and social services, but noted they are optimistic about new appropriations for the second half of the year.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts